Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial

Vincent C. Marconi(Emory University), E. Wesley Ely(Vanderbilt University), Ran Liao(Jiujiang First People's Hospital), Vicente Estrada(Instituto de Salud Carlos III), Maria Lucia Buziqui Piruzeli(Eli Lilly (United States)), Athimalaipet V Ramanan(University of Bristol), Jorge Alatorre-Alexander, Jason D. Goldman(University of Washington), Rita de Cassia Pellegrini(Beneficência Portuguesa de São Paulo), Paulo Reis(Eli Lilly (United States)), Venkatesh Krishnan(Eli Lilly (United States)), Anabela Cardoso(Eli Lilly (United States)), Sujatro Chakladar(Eli Lilly (United States)), David H. Adams(Eli Lilly (United States)), Brenda Crowe(Eli Lilly (United States)), Xin Zhang(Wuhan University), Cynthia E. Kartman(Eli Lilly (United States)), Mousumi Som(Oklahoma State University), Stephanie de Bono(Eli Lilly (United States))
medRxiv
May 3, 2021
10.1101/2021.04.30.21255934
Cited by 36

Related Papers

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Delirium
|Nature Reviews Disease Primers|2020|1.1k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818